Company Encyclopedia
View More
name
Tivic Health
TIVC.US
Tivic Health Systems, Inc., a health tech company, develops and commercializes bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for use in the treatment of sinus pain, pressure, and congestion. The company sells its products through online retailers and commercial distributors, as well as its own website. Its lead product candidate is Entolimod, a late-stage TLR5 agonist for use in the treatment of acute radiation syndrome.
1.399 T
TIVC.USMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking149/174
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-179.30%E
    • Profit Margin-1557.26%E
    • Gross Margin-99.32%E
  • Growth ScoreD
    • Revenue YoY-49.63%E
    • Net Profit YoY-17.63%D
    • Total Assets YoY83.53%A
    • Net Assets YoY97.28%A
  • Cash ScoreD
    • Cash Flow Margin-6.38%D
    • OCF YoY-49.63%E
  • Operating ScoreE
    • Turnover0.1E
  • Debt ScoreA
    • Gearing Ratio10.24%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    During Tuesday's pre-market session, Tivic Health Systems stock rose 47.5%, Cue Biopharma increased by 12.38%, and Neumora Therapeutics gained 11.6%. Meanwhile, CytoSorbents stock fell 12.5%, Akanda declined by 9.18%, and GridAI Technologies dropped 8.61%. The article highlights significant stock movements in the health care sector.

    benzinga_article·
    US
    NMRA
    -4.70%
    US
    TIVC
    +30.66%
    US
    CUE
    -1.03%
    benzinga_article·
    US
    NMRA
    -4.70%
    US
    TIVC
    +30.66%
    US
    CUE
    -1.03%

    Tivic Health Secures $16M Debt Financing Led by 3i for Manufacturing Asset Acquisition

    Tivic Health Systems Inc. has secured $16 million in debt financing led by 3i, LP for acquiring manufacturing and development assets. The financing includes equipment and facility improvements, with access to up to $75 million in preferred convertible equity and a $50 million equity line of credit from 3i, LP to support growth initiatives.

    Reuters·
    US
    TIVC
    +30.66%
    Reuters·
    US
    TIVC
    +30.66%

    Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package | TIVC Stock News

    Tivic Health Systems has acquired manufacturing and development assets from Scorpius Holdings, launching a new subsidiary, Velocity Bioworks, to enhance its manufacturing capabilities. This acquisition, backed by over $90M in financing led by 3i, LP, aims to accelerate the commercialization of Tivic's lead drug candidate, Entolimod, and create new revenue opportunities. The financing includes $16M in debt and up to $75M in preferred convertible equity. Additionally, Tivic plans to grant stock options to new employees as part of the acquisition.

    StockTitan·
    US
    TIVC
    +30.66%
    StockTitan·
    US
    TIVC
    +30.66%

    Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome

    Tivic Health Systems has secured a Techwatch meeting with BARDA's Radiological and Nuclear Medical Countermeasures Program to discuss Entolimod for acute radiation syndrome. The meeting will cover clinical data, manufacturing readiness, and a biologics license application. Entolimod, a TLR5 agonist, has shown promising results in trials and has FDA Fast Track and Orphan Drug designations. This interaction aligns with Tivic's strategy to develop high-value therapeutic assets with potential government partnerships.

    Acceswire·
    US
    TIVC
    +30.66%
    Acceswire·
    US
    TIVC
    +30.66%

    Tivic Health’s Earnings Call: Strategic Shift and Challenges

    Tivic Health Systems, Inc. held its Q3 earnings call, highlighting its strategic shift from bioelectronics to biologic pharmaceuticals, focusing on immune system treatments. Despite challenges like increased net loss and manufacturing delays, the company improved its financial position with cash reserves rising to $3.5 million and a debt-free balance sheet. Gross margins improved to 42%, though net loss increased to $2.6 million. Tivic is optimistic about its future, focusing on Entolimod development as a military countermeasure, despite decreased nine-month revenue.

    Tip Ranks·
    US
    TIVC
    +30.66%
    Tip Ranks·
    US
    TIVC
    +30.66%
    © 2025 Longbridge｜Disclaimer